In an open-label RCT, 99 ND-CKD patients with IDA (Hb ≤ 12 g/dL, ferritin ≤ 100 ng/mL, TSAT ≤ 25%) were assigned (2:1) to receive oral SI (30 mg/day) for 3 months or IV FG (125 mg/week; cumulative dose, 1000 mg) [65]. This evidence concerns the gene GSTM1 and chronic kidney disease.